March 29, 2021 05:19 PM EDTUpdated April 3, 11:33 AM

FDA busts Merck's Keytruda in triple-negative breast cancer with a CRL — not unexpected given its disastrous adcomm

Kyle Blankenship

Merck and the FDA have engaged in a high-noon standoff over checkpoint inhibitor Keytruda in triple-negative breast cancer after the agency roundly panned its results …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA busts Merck's Keytruda in triple-negative breast cancer with a CRL — not unexpected given its disastrous adcomm

Kyle Blankenship

Sign up to read this article for free.

Ideaya inks ADC deal with $75M upfront; Amylyx, Gubra to develop long-acting GLP-1

Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

WuXi AppTec will sell cell and gene therapy business to private equity firm

FDA approves subcutaneous version of Bristol Myers' Opdivo

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

FDA busts Mer­ck­'s Keytru­da in triple-neg­a­tive breast can­cer with a CRL — not un­ex­pect­ed giv­en its dis­as­trous ad­comm

Kyle Blankenship

Sign up to read this article for free.

more like this

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

FDA busts Merck's Keytruda in triple-negative breast cancer with a CRL — not unexpected given its disastrous adcomm

Ideaya inks ADC deal with $75M upfront; Amylyx, Gubra to develop long-acting GLP-1

Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

WuXi AppTec will sell cell and gene therapy business to private equity firm

FDA approves subcutaneous version of Bristol Myers' Opdivo

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties